Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cP12 in Otherwise Healthy Adults With Thermal Burns
NCT06814717Phase 2Recruiting
- Sponsor
- NeoMatrix Therapeutics
- Start
- May 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of cP12 in thermal burn, sponsored by NeoMatrix Therapeutics. Started May 2025; status: recruiting.
02
Drugs
cP12
03
Conditions
thermal burn
Beyond the preview
Go deeper on NCT06814717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06814717.